New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroidsAstraZeneca’s Fasenra (benralizumab) ...
(Alliance News) - AstraZeneca PLC on Wednesday announced Fasenra has been approved in the US to treat adult patients with eosinophilic granulomatosis with polyangiitis, or EGPA. The Cambridge, ...
(IN BRIEF) AstraZeneca’s Fasenra (benralizumab) has been approved by the US FDA for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA), a rare immune-mediated vasculitis that can be ...
Some results have been hidden because they may be inaccessible to you